PCIA
IBB icon

Prime Capital Investment Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Prime Capital Investment Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$679K Sell
3,572
-879
-20% -$151K 0.01% 614
2026
Q1 		$752K Sell
4,451
-137
-3% -$23.4K 0.01% 570
2025
Q4 		$774K Sell
4,588
-730
-14% -$119K 0.01% 544
2025
Q3 		$768K Sell
5,318
-4,609
-46% -$629K 0.01% 536
2025
Q2 		$1.26M Sell
9,927
-10,355
-51% -$1.27M 0.02% 429
2025
Q1 		$2.59M Buy
20,282
+2,806
+16% +$380K 0.03% 318
2024
Q4 		$2.31M Sell
17,476
-833
-5% -$117K 0.03% 286
2024
Q3 		$2.67M Sell
18,309
-462
-2% -$66.8K 0.04% 273
2024
Q2 		$2.58M Sell
18,771
-1,463
-7% -$195K 0.04% 279
2024
Q1 		$2.78M Sell
20,234
-33,675
-62% -$4.6M 0.04% 290
2023
Q4 		$7.32M Buy
53,909
+15,019
+39% +$1.83M 0.11% 155
2023
Q3 		$4.76M Buy
38,890
+22,374
+135% +$2.85M 0.1% 161
2023
Q2 		$2.1M Buy
16,516
+10,443
+172% +$1.36M 0.04% 253
2023
Q1 		$784K Sell
6,073
-12,457
-67% -$1.63M 0.03% 280
2022
Q4 		$2.43M Buy
18,530
+16,185
+690% +$2.09M 0.09% 156
2022
Q3 		$274K Sell
2,345
-22,021
-90% -$2.73M 0.02% 325
2022
Q2 		$2.87M Sell
24,366
-10,292
-30% -$1.22M 0.17% 103
2022
Q1 		$5.29M Hold
34,658
– – 0.29% 68
2021
Q4 		$5.29M Buy
34,658
+31,761
+1,096% +$4.92M 0.28% 72
2021
Q3 		$468K Sell
2,897
-852
-23% -$143K 0.03% 220
2021
Q2 		$614K Buy
3,749
+739
+25% +$114K 0.04% 229
2021
Q1 		$453K Sell
3,010
-30,341
-91% -$4.82M 0.03% 198
2020
Q4 		$5.05M Buy
33,351
+5,044
+18% +$721K 0.39% 39
2020
Q3 		$3.83M Buy
28,307
+4,652
+20% +$631K 0.32% 56
2020
Q2 		$3.23M Buy
23,655
+4,615
+24% +$588K 0.3% 66
2020
Q1 		$2.05M Buy
19,040
+7,965
+72% +$917K 0.24% 76
2019
Q4 		$1.33M Buy
+11,075
New +$1.24M 0.15% 119
2018
Q3 		– Sell
-6
Closed -$1K – 304
2018
Q2 		$1K Buy
+6
New +$642 ﹤0.01% 342

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Prime Capital Investment Advisors's IBB Position: Q2 2026 in Review

Prime Capital Investment Advisors reduced its iShares Biotechnology ETF (IBB) stake by 20% in Q2 2026, selling an estimated $151K and leaving 3,572 shares worth $679K. The position accounts for 0.01% of the portfolio, ranked #614.

Prime Capital Investment Advisors first reported a position in IBB in Q2 2018 and has held it in 28 quarters since. The position peaked at $7.32M in Q4 2023. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Prime Capital Investment Advisors held 3,572 shares of iShares Biotechnology ETF worth $679K as of Q2 2026.
  • Prime Capital Investment Advisors sold 879 iShares Biotechnology ETF shares in Q2 2026, an estimated $151K.
  • iShares Biotechnology ETF made up 0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #614 holding.
  • Prime Capital Investment Advisors first reported a position in iShares Biotechnology ETF in Q2 2018 and has held it in 28 quarters since.
  • Prime Capital Investment Advisors's iShares Biotechnology ETF position peaked at $7.32M in Q4 2023.
  • 960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.